Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
A phase 3 trial testing TQB3616 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.
Overview
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer is a phase 3 interventional study registered as NCT05780567, led by Chia Tai Tianqing Pharmaceutical, and active but no longer recruiting when checked on 2026-09-11. Official title: Randomised, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of TQB3616 Combined With Endocrine Therapy Versus Placebo Combined With Endocrine Therapy in Hormone Receptors (HR)-Positive and Human Epidermal GrowthFactor Receptor-2 (HER2) -Negative Breast Cancer Adjuvant Therapy. Planned enrolment is 1946 participants (estimated). The study started in 2023-03-30 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialTo Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Shares TQB3616, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.